Overview

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Status:
Active, not recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Riociguat